Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Neoplasms 2Meningioma 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neurofibromatosis 2 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Endometrial Neoplasms 1Disease 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 12gallium Ga 68 dotatate 6Everolimus 6lutetium Lu 177 dotatate 5Radiosurgery 5Proton Therapy 5Bevacizumab 5pembrolizumab 4Surveys and Questionnaires 4Specimen Handling 4Hydroxyurea 4abemaciclib 3Tranexamic Acid 3Surgical Procedures, Operative 3Sodium Chloride 3Ga(III)-DOTATOC 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vistusertib 2trametinib 2ribociclib 2arginyllysine 2aldesleukin 2Yoga 2Whole Body Imaging 2Sunitinib 2Saline Solution 2Ropivacaine 2Radiotherapy 2Protons 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Meningioma × vistusertib × Clear all
NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown
28 enrolled
CNS

Meningioma

NCT02831257 2022-06-13

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Massachusetts General Hospital

Phase 2 Completed
18 enrolled 13 charts
CNS

Meningioma, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡